News & Updates

Show Multimedia Only

Oral steroids can up CVD risk, even at low doses

31 Jan 2021 by

Use of oral glucocorticoid is associated with an increased risk of cardiovascular diseases (CVDs), even at low doses of <5 mg prednisone-equivalent daily in patients with immune-mediated inflammatory diseases, a large study reveals.

Oral steroids can up CVD risk, even at low doses

31 Jan 2021

Filgotinib scores in RA patients with limited or no MTX exposure

28 Jan 2021 by

The Janus kinase (JAK)-1 inhibitor filgotinib delivers meaningful benefits for signs and symptoms of rheumatoid arthritis (RA), as well as physical function, in patients with limited or no prior exposure to methotrexate (MTX), according to the results of the phase III FINCH 3 trial.

Filgotinib scores in RA patients with limited or no MTX exposure

28 Jan 2021

Amiselimod exhibits favourable safety in healthy individuals

27 Jan 2021 by

Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.

Amiselimod exhibits favourable safety in healthy individuals

27 Jan 2021

Sexual problems in men with ankylosing spondylitis tied to disease activity

26 Jan 2021

Male patients with ankylosing spondylitis appear to have poor sexual performance, and this problem is associated with disease activity rather than sexual hormonal profile, according to a study.

Sexual problems in men with ankylosing spondylitis tied to disease activity

26 Jan 2021

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

22 Jan 2021 by

Romilkimab – a novel engineered, humanized immunoglobulin(Ig)-G4 antibody – delivers significant skin benefits for individuals with early diffuse cutaneous systemic sclerosis (dcSSc), a subtype of SSc, a phase II proof-of-concept study has shown.

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

22 Jan 2021

Acute flares do not last long on febuxostat

21 Jan 2021

In patients with gout, treatment with febuxostat does not appear to prolong the duration of acute flares, a study has shown.

Acute flares do not last long on febuxostat

21 Jan 2021

Flat flexible vs stable supportive shoes: which is better at reducing knee OA symptoms?

18 Jan 2021

Flat flexible shoes do not appear to be better than stable supportive shoes for patients with knee osteoarthritis (OA) symptoms, according to a study.

Flat flexible vs stable supportive shoes: which is better at reducing knee OA symptoms?

18 Jan 2021

Vitamin D plus protein helps strengthen but not bulk up muscle in sarcopenia

16 Jan 2021

In patients with sarcopenia, vitamin D supplementation in combination with protein increases muscle strength but falls short of improving muscle mass or performance, according to the results of a systematic review and meta-analysis.

Vitamin D plus protein helps strengthen but not bulk up muscle in sarcopenia

16 Jan 2021

TNFi plus csDMARD does not improve disease activity, HAQ in psoriatic arthritis

16 Jan 2021

Tumour necrosis factor inhibitor (TNFi) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) does not appear to be any better than TNFi monotherapy at improving disease activity or Health Assessment Questionnaire (HAQ) in patients with psoriatic arthritis (PsA), reports a study. However, the combination therapy may improve TNFi survival.

TNFi plus csDMARD does not improve disease activity, HAQ in psoriatic arthritis

16 Jan 2021

Patients with ankylosing spondylitis at risk of hearing loss

15 Jan 2021

The likelihood of having hearing loss (HL) is higher among patients with ankylosing spondylitis (AS) than those without, according to a new study.

Patients with ankylosing spondylitis at risk of hearing loss

15 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

Oral steroids can up CVD risk, even at low doses

Oral steroids can up CVD risk, even at low doses

Filgotinib scores in RA patients with limited or no MTX exposure

Filgotinib scores in RA patients with limited or no MTX exposure

Amiselimod exhibits favourable safety in healthy individuals

Amiselimod exhibits favourable safety in healthy individuals

Sexual problems in men with ankylosing spondylitis tied to disease activity

Sexual problems in men with ankylosing spondylitis tied to disease activity

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

Acute flares do not last long on febuxostat

Acute flares do not last long on febuxostat

Flat flexible vs stable supportive shoes: which is better at reducing knee OA symptoms?

Flat flexible vs stable supportive shoes: which is better at reducing knee OA symptoms?

Vitamin D plus protein helps strengthen but not bulk up muscle in sarcopenia

Vitamin D plus protein helps strengthen but not bulk up muscle in sarcopenia

TNFi plus csDMARD does not improve disease activity, HAQ in psoriatic arthritis

TNFi plus csDMARD does not improve disease activity, HAQ in psoriatic arthritis

Patients with ankylosing spondylitis at risk of hearing loss

Patients with ankylosing spondylitis at risk of hearing loss